zoledronic acid has been researched along with HIV Coinfection in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 3 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Collins, LF; Easley, KA; Foster, A; Lahiri, CD; Lennox, JL; Moran, CA; Ofotokun, I; Sheth, AN; Titanji, K; Ward, L; Weitzmann, MN | 1 |
| Akpa, AA; Bathily, M; Berthe, D; Cisse, HL; Dao, S; Dembele, JP; Diabate, K; Diakite, A; Diallo, DA; Diarra, B; Diarra, IM; Fofana, Y; Guindo, I; Konate, M; Kone, AA; Kone, AC; Kone, AS; Kone, J; Minta, D; Ouattara, BZ; Sidibe, A; Sidibe, FM; Sidibe, S; Soumare, MD; Toloba, Y; Toure, BA | 1 |
| Duan, L; Li, XF; Lin, W; Liu, JZ; Ren, DC; Song, M; Zhan, ZR | 1 |
| Chaudhry, S; Murday, AS; Pauza, CD | 1 |
| Carr, A; Ebeling, PR; Hoy, JF; Kerr, SJ; Martinez, E; Pocock, N; Richardson, R; Rojas, J | 1 |
| Bolland, MJ; Briggs, SE; Gamble, GD; Grey, A; Horne, AM; Reid, I; Thomas, MG | 1 |
| Carr, A; Ebeling, P; Hoy, J; Kerr, SJ; Martinez, E; Pocock, N; Richardson, R; Rojas, J | 1 |
| Bolland, MJ; Grey, A; Horne, AM; Reid, IR | 1 |
| Chen, WW; Nie, WM; Wu, XL; Xie, YX; Xu, W; Yang, JL; Zhao, M | 1 |
| Bonjoch, A; Clotet, B; del Río, L; di Gregorio, S; Echeverría, P; Estany, C; Herrero, C; Negredo, E; Ornelas, A; Pérez-Álvarez, N; Puig, J | 1 |
| Negredo, E; Warriner, AH | 1 |
| Poonia, B | 1 |
| Easley, KA; Foster, A; Knezevic, A; Lahiri, CD; Lennox, JL; Ofotokun, I; Powers, P; Sanford, SE; Sheth, AN; Titanji, K; Vunnava, A; Ward, L; Weitzmann, MN | 1 |
| Bolland, MJ; Briggs, SE; Callon, KE; Ellis-Pegler, RB; Gamble, GD; Grey, AB; Horne, AM; Reid, IR; Thomas, MG | 1 |
| Fernandez, S; Huang, J; McCutchan, JA; Meixner, L | 1 |
| Abdeddaim, A; Agrati, C; Amendola, A; D'Offizi, G; Gioia, C; Malkovsky, M; Martini, F; Piacentini, P; Poccia, F; Sacchi, A; Tempestilli, M; Vlassi, C | 1 |
| Pauza, CD; Poonia, B | 1 |
| Bolland, MJ; Briggs, SE; Ellis-Pegler, RB; Gamble, GD; Grey, A; Horne, AM; Reid, IR; Thomas, MG | 1 |
| Bolland, MJ; Briggs, SE; Ellis-Pegler, RB; Gamble, GD; Grey, AB; Horne, AM; Reid, IR; Thomas, MG; Woodhouse, AF | 1 |
2 review(s) available for zoledronic acid and HIV Coinfection
| Article | Year |
|---|---|
[Gastrointestinal symptoms revealing COVID-19 in Malian breast cancer patient undergoing chemotherapy].
Topics: Adult; Antineoplastic Agents, Phytogenic; Betacoronavirus; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Coronavirus Infections; COVID-19; Diarrhea; Docetaxel; Fatal Outcome; Female; HIV Infections; Humans; Liver Neoplasms; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spinal Neoplasms; Tomography, X-Ray Computed; Vomiting; Zoledronic Acid | 2020 |
Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients.
Topics: Alendronate; Anti-Inflammatory Agents; Bone Density; Bone Density Conservation Agents; Diphosphonates; HIV Infections; Humans; Imidazoles; Osteoporosis; Zoledronic Acid | 2016 |
12 trial(s) available for zoledronic acid and HIV Coinfection
| Article | Year |
|---|---|
Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; HIV Infections; Humans; Imidazoles; Zoledronic Acid | 2020 |
Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.
Topics: Adult; Anti-Retroviral Agents; Bone Density; Bone Density Conservation Agents; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Female; HIV Infections; Humans; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Osteoclasts; Osteogenesis; Osteoporosis; RANK Ligand; Smad3 Protein; Tenofovir; Zoledronic Acid | 2021 |
Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
Topics: Absorptiometry, Photon; Adult; Aged; Anti-HIV Agents; Australia; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Drug Substitution; Female; Femur Neck; HIV Infections; Humans; Lumbar Vertebrae; Male; Middle Aged; Spain; Tenofovir; Treatment Outcome; Viral Load; Zoledronic Acid | 2018 |
Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
Topics: Adult; Biomarkers; Bone Density; Bone Remodeling; Female; Fractures, Bone; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Zoledronic Acid | 2019 |
Testosterone levels following decreases in serum osteocalcin.
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Follow-Up Studies; HIV Infections; Humans; Imidazoles; Luteinizing Hormone; Male; Middle Aged; Osteocalcin; Testis; Testosterone; Time Factors; Zoledronic Acid | 2013 |
Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years.
Topics: Absorptiometry, Photon; Antiretroviral Therapy, Highly Active; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Directive Counseling; Dose-Response Relationship, Drug; Drug Administration Schedule; Feeding Behavior; Female; HIV Infections; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Pelvic Bones; Pilot Projects; Treatment Outcome; Zoledronic Acid | 2015 |
A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial.
Topics: Adult; Anti-Retroviral Agents; Bone Density Conservation Agents; Diphosphonates; Female; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; RNA, Viral; Zoledronic Acid | 2016 |
Effects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months.
Topics: Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; HIV Infections; Humans; Imidazoles; Injections, Intravenous; Male; Middle Aged; Placebos; Time Factors; Zoledronic Acid | 2008 |
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.
Topics: Adult; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Calcium, Dietary; Diphosphonates; Double-Blind Method; Female; Hip Joint; HIV Infections; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Treatment Outcome; Zoledronic Acid | 2009 |
Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
Topics: Adjuvants, Immunologic; Cell Differentiation; Cells, Cultured; Cytotoxicity, Immunologic; Dendritic Cells; Diphosphonates; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Imidazoles; Immunocompetence; Immunologic Memory; Immunophenotyping; Interleukin-2; Lymphocyte Activation; Lymphocyte Count; Receptors, Antigen, T-Cell, gamma-delta; Recombinant Proteins; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Zoledronic Acid | 2009 |
Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; HIV Infections; Humans; Imidazoles; Injections, Intravenous; Male; Markov Chains; Middle Aged; Osteocalcin; Peptides; Zoledronic Acid | 2012 |
Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Body Mass Index; Body Size; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Placebos; Zoledronic Acid | 2007 |
5 other study(ies) available for zoledronic acid and HIV Coinfection
| Article | Year |
|---|---|
Interleukin-18 activates Vγ9Vδ2
Topics: Antigens; Cell Proliferation; Cells, Cultured; Diphosphonates; Hemiterpenes; HIV Infections; HIV-1; Humans; Imidazoles; Immunologic Memory; Immunophenotyping; Immunotherapy; Interleukin-18; Killer Cells, Natural; Lymphocyte Activation; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2017 |
Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least 11 Years in HIV-Infected Men.
Topics: Administration, Intravenous; Bone Density; Bone Remodeling; Collagen Type I; Dose-Response Relationship, Drug; HIV Infections; Humans; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Zoledronic Acid | 2019 |
[The comparison between HIV-infected patients' Vdelta2 T cells expansion efficiencies by zoledronic acid and gammadelta TCR monoclonal antibody in vitro].
Topics: Adult; Antibodies, Monoclonal; Case-Control Studies; Cell Proliferation; Cells, Cultured; Diphosphonates; Female; Flow Cytometry; HIV Infections; Humans; Imidazoles; Leukocytes, Mononuclear; Lymphocyte Count; Male; Middle Aged; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Zoledronic Acid | 2012 |
Adoptive transfer of aminobisphonate-expanded Vγ9Vδ2+ T cells does not control HIV replication in a humanized mouse model.
Topics: Adoptive Transfer; Animals; Antibodies, Monoclonal; CD4-Positive T-Lymphocytes; Cell Proliferation; Diphosphonates; Disease Models, Animal; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Imidazoles; Mice; Mice, Inbred NOD; Mice, SCID; Receptors, Antigen, T-Cell, gamma-delta; Receptors, CCR5; Viremia; Virus Replication; Zoledronic Acid | 2016 |
Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity.
Topics: Anti-Retroviral Agents; Antibody-Dependent Cell Cytotoxicity; CD56 Antigen; Cell Line, Tumor; Diphosphonates; GPI-Linked Proteins; Hemiterpenes; HIV; HIV Infections; Humans; Imidazoles; Immunophenotyping; Interleukin-2; Lymphocyte Activation; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; Receptors, IgG; T-Lymphocytes; Zoledronic Acid | 2012 |